We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
- Authors
Piccart, M J; Bertelsen, K; James, K; Cassidy, J; Mangioni, C; Simonsen, E; Stuart, G; Kaye, S; Vergote, I; Blom, R; Grimshaw, R; Atkinson, R J; Swenerton, K D; Trope, C; Nardi, M; Kaern, J; Tumolo, S; Timmers, P; Roy, J A; Lhoas, F; Lindvall, B; Bacon, M; Birt, A; Andersen, J E; Zee, B; Paul, J; Baron, B; Pecorelli, S
- Abstract
A randomized trial conducted by the Gynecologic Oncology Group (GOG, study #111) in the United States showed a better outcome for patients with advanced ovarian cancer on the paclitaxel-cisplatin regimen than for those on a standard cyclophosphamide-cisplatin regimen. Before considering the paclitaxel-cisplatin regimen as the new "standard," a group of European and Canadian investigators planned a confirmatory phase III trial.
- Publication
Journal of the National Cancer Institute, 2000, Vol 92, Issue 9, p699
- ISSN
0027-8874
- Publication type
Journal Article
- DOI
10.1093/jnci/92.9.699